Organic E. will get WHO section II nod for novel oral polio vaccine

Organic E. has acquired section II pre-qualification of the World Well being Organisation for its novel oral polio vaccine kind 2 (nOPV2).

The section II PQ covers each drug substance and drug product manufactured at BE, finishing the complete manufacturing chain for nOPV2 at a single built-in web site. It expands BE’s WHO-qualified manufacturing scope past Part I, below which the corporate acquired PQ in June 2024 for drug product manufacturing utilizing externally equipped drug substance, the Hyderabad-based vaccine maker mentioned on Thursday.

BE mentioned it has already manufactured and equipped 700 million doses of nOPV2 to the product stockpile and shipped to a number of international locations the place the immunisation campaigns are below technique to management circulating vaccine-derived poliovirus kind 2 (cVDPV2) outbreaks.

“When polio outbreaks happen, response time and vaccine availability decide how shortly transmission will be stopped. With section II WHO pre-qualification enabling full end-to-end manufacturing at our amenities, international provide turns into extra resilient and extra responsive,” BE managing director Mahima Datla mentioned.

nOPV2 has already been deployed over a billion doses globally as a result of it’s designed particularly for outbreak management with improved genetic stability, she mentioned.

The expanded qualification considerably strengthens international outbreak response readiness by including built-in, WHO-qualified manufacturing capability for nOPV2 — a vital vaccine utilized in controlling cVDPV2 outbreaks.

The achievement displays a multi-year, multi-partner international collaboration involving know-how switch, product comparability evaluation, specialised testing and manufacturing readiness programmes throughout establishments. “The progress displays the vital contributions of PT Bio Farma (Indonesia), PATH and the Gates Basis in technical and programmatic assist,” Ms.Datla mentioned.